Enzalutamide in Metastatic Prostate Cancer Before Chemotherapy

50 Studies Every Urologist Should Know Pub Date : 2021-02-01 DOI:10.1093/MED/9780190655341.003.0018

J. Zabell

引用次数: 19

Abstract

This chapter summarizes the findings of the landmark PREVAIL trial conducted in men with castrate-resistant prostate cancer who had received prior chemotherapy comparing enzalutamide to placebo. It demonstrated improved overall survival, radiographic progression-free survival, and time to cytotoxic chemotherapy.

查看原文本刊更多论文

恩杂鲁胺在化疗前转移性前列腺癌中的作用

本章总结了具有里程碑意义的PREVAIL试验的结果，该试验在接受过化疗的去势抵抗性前列腺癌患者中进行，并将enzalutamide与安慰剂进行了比较。它证明了总生存期、放射学无进展生存期和细胞毒性化疗时间的改善。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

50 Studies Every Urologist Should Know

自引率

0.00%

发文量